Author, as appears in the article.: Pehrsson M; Manon-Jensen T; Sun S; Villesen IF; Castañé H; Joven J; Patel K; Goodman Z; Nielsen MJ; Bay-Jensen AC; Leeming DJ; Mortensen JH; Karsdal MA
Department: Medicina i Cirurgia
URV's Author/s: Castañé Vilafranca, Helena / Joven Maried, Jorge
Keywords: Non-invasive biomarkers Hepatic fibrosis Fibrosis resolution Fatty liver-disease Collagen cross-linking sampling variability progression pro-c3 non-invasive biomarkers hepatic fibrosis fibrosis resolution
Abstract: Liver fibrosis results from a prolonged wound healing response to continued injury with excessive production of extracellular proteins. In patients with chronic liver disease, the monitoring of liver fibrosis dynamics is of high interest. While markers of fibrogenesis exist, markers of hepatic fibrosis resolution remain an unmet clinical need. Thus we sought to develop an assay quantifying a circulating proteolytic fragment of cross-linked type III collagen as a biomarker of fibrolysis, testing its utility in two clinical cohorts of liver fibrosis of distinct aetiology and regressing endotype.We used a monoclonal antibody targeting the C-telopeptide of type III collagen following C-proteinase cleavage to develop and validate a neo-epitope-specific enzyme-linked immunosorbent assay (CTX-III). A potential fibrosis resolution marker, CTX-III, was measured in two clinical cohorts of patients with obesity-associated non-alcoholic fatty liver disease undergoing bariatric surgery or hepatitis C virus infection from a clinical trial study evaluating the anti-fibrotic effect of farglitazar.CTX-III was robust and specific for the targeted neo-epitope with good reproducibility in EDTA plasma. We assessed type III collagen remodelling using a panel of biomarkers, including a type III collagen formation marker (PRO-C3), degradation (C3M), and CTX-III (fibrolysis). Net fibrolysis was increased in patients with non-alcoholic fatty liver disease following bariatric surgery (p<0.001). Moreover, net fibrolysis identified spontaneous fibrotic regressors from stable and progressors (p<0.05 and p<0.001) among hepatitis C virus infection patients.Circulating CTX-III as a marker of fibrolysis, indicating the biomarker's beneficial use in assessing hepatic fibrosis resolution.This article is protected by copyright. All rights reserved.
Thematic Areas: Saúde coletiva Nutrição Medicina veterinaria Medicina iii Medicina ii Medicina i Interdisciplinar Hepatology General medicine Gastroenterology & hepatology Farmacia Engenharias iv Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciência de alimentos Biotecnología Astronomia / física
licence for use: https://creativecommons.org/licenses/by/3.0/es/
Author's mail: helena.castane@estudiants.urv.cat jorge.joven@urv.cat
Author identifier: 0000-0003-2749-4541
Record's date: 2024-09-07
Papper version: info:eu-repo/semantics/publishedVersion
Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
Papper original source: Liver International. 42 (7): 1605-1617
APA: Pehrsson M; Manon-Jensen T; Sun S; Villesen IF; Castañé H; Joven J; Patel K; Goodman Z; Nielsen MJ; Bay-Jensen AC; Leeming DJ; Mortensen JH; Karsdal M (2022). An MMP-degraded and cross-linked fragment of type III collagen as a non-invasive biomarker of hepatic fibrosis resolution. Liver International, 42(7), 1605-1617. DOI: 10.1111/liv.15270
Entity: Universitat Rovira i Virgili
Journal publication year: 2022
Publication Type: Journal Publications
Repositori URV